Sugi Predict

Sugi Predict / Compounds / SCHEMBL9252175

SCHEMBL9252175

SCHEMBL9252175

C=Cc1ccc(C(=O)C(C)C)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAS1R3 Q7RTX0 3/20 0.51
▸ TAS1R1 Q7RTX1 3/20 0.51
▸ KDM4E B2RXH2 1/20 0.47
▸ DBH P09172 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ ALDH1A1 P00352 5/20 0.46
▸ TDP1 Q9NUW8 2/20 0.41
▸ TSHR P16473 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.35
▸ PTGS2 P35354 2/20 0.35
▸ SLC6A2 P23975 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ ALDH5A1 P51649 1/20 0.33
▸ ABAT P80404 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22548919 0.83 KDM4E (0.50) KDM4EDBHGAARECQLALDH1A1
SCHEMBL23419503 0.83 ALDH1A1 (0.50) TAS1R3TAS1R1ALDH1A1TDP1TSHR
SCHEMBL10121174 0.82 KDM4E (0.62) KDM4EDBHGAARECQLALDH1A1
SCHEMBL18265600 0.81 TAS1R3 (0.50) TAS1R3TAS1R1KDM4EGAAALDH1A1
SCHEMBL7402179 0.81 ALDH1A1 (0.56) KDM4EDBHGAARECQLALDH1A1
SCHEMBL7495938 0.79 KDM4E (0.47) TAS1R3TAS1R1KDM4EDBHGAA
SCHEMBL22541313 0.79 KDM4E (0.47) TAS1R3TAS1R1KDM4EDBHGAA
SCHEMBL23190972 0.79 TAS1R3 (0.51) TAS1R3TAS1R1KDM4EGAAALDH1A1
SCHEMBL30306602 0.78 ALDH1A1 (0.44) TAS1R3TAS1R1ALDH1A1TDP1TSHR
SCHEMBL3757038 0.78 CES2 (0.55) TAS1R3TAS1R1KDM4EALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410114-B2 Process for the preparation of α-functionalized ketones IGM GROUP B.V. (NL) 2025-09-09 — — US disclosed
US-20230158141-A1 Conjugates of Biomolecule and Use Thereof YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOG (CN) 2023-05-25 — — US disclosed
US-20230158141-A1 Conjugates of Biomolecule and Use Thereof YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOG (CN) 2023-05-25 — — US disclosed
CN-110494414-B Process for the preparation of alpha-functionalized ketones IGM集团私人有限公司 2022-07-12 — — CN disclosed
EP-3395793-B9 PROCESS FOR THE PREPARATION OF ALPHA-FUNCTIONALIZED KETONES IGM GROUP B V (NL) 2021-09-29 — — EP disclosed
EP-3395793-B1 PROCESS FOR THE PREPARATION OF ALPHA-FUNCTIONALIZED KETONES IGM GROUP B V (NL) 2021-03-17 — — EP disclosed
EP-3615501-A1 PROCESS FOR THE PREPARATION OF ALPHA-FUNCTIONALIZED KETONES IGM Group B.V. (NL) 2020-03-04 — — EP disclosed
US-20200055806-A1 PROCESS FOR THE PREPARATION OF ALPH-FUNCTIONALIZED KETONES IGM GROUP B.V. (NL) 2020-02-20 — — US disclosed
WO-2018197325-A1 PROCESS FOR THE PREPARATION OF ALPHA-FUNCTIONALIZED KETONES IGM GROUP B.V. (NL) 2018-11-01 — — WO disclosed
EP-3395793-A1 PROCESS FOR THE PREPARATION OF ALPHA-FUNCTIONALIZED KETONES IGM Group B.V. (NL) 2018-10-31 — — EP disclosed
US-8524689-B2 Antibacterial aminoglycoside analogs ACHAOGEN, INC. (US) 2013-09-03 — — US disclosed
US-20120208781-A1 AMINOGLYCOSIDE DOSING REGIMENS ACHAOGEN, INC. (US) 2012-08-16 — — US disclosed
US-20120208781-A1 AMINOGLYCOSIDE DOSING REGIMENS ACHAOGEN, INC. (US) 2012-08-16 — — US disclosed
US-20120135948-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2012-05-31 — — US disclosed
WO-2010132839-A9 AMINOGLYCOSIDE DOSING REGIMENS ACHAOGEN, INC. (US) 2011-09-15 — — WO disclosed
WO-2010132757-A9 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2011-08-25 — — WO disclosed
WO-2010132839-A2 AMINOGLYCOSIDE DOSING REGIMENS ACHAOGEN, INC. (US) 2010-11-18 — — WO disclosed
WO-2010132757-A2 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-11-18 — — WO disclosed
EP-0391212-B1 Process for preparing bifunctional Z-stilbene compounds, new bifunctional Z-stilbene compounds and their use for preparing polymers BAYER AG (DE) 1994-05-25 — — EP disclosed
EP-0391212-A2 Process for preparing bifunctional Z-stilbene compounds, new bifunctional Z-stilbene compounds and their use for preparing polymers BAYER AG (DE) 1990-10-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135948-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, NQO2, QARS1 TAS1R3 2998/4885TAS1R1 3644/4885KDM4E 3622/4885
US-20200055806-A1 PROCESS FOR THE PREPARATION OF ALPH-FUNCTIONALIZED KETONES AKR1C2, AKR1C1, PHYKPL TAS1R3 4273/4885TAS1R1 4214/4885KDM4E 723/4885
US-20230158141-A1 Conjugates of Biomolecule and Use Thereof CD47, FCGR2A, CD40 TAS1R3 4306/4885TAS1R1 4137/4885KDM4E 2983/4885
US-12410114-B2 Process for the preparation of α-functionalized ketones PCCA, PRKCD, AKR1C1 TAS1R3 3507/4885TAS1R1 3278/4885KDM4E 765/4885
US-20120208781-A1 AMINOGLYCOSIDE DOSING REGIMENS ATP6V1B1, GLS, NRDC TAS1R3 2873/4885TAS1R1 2706/4885KDM4E 4645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.